Related Experiment Videos
Topical indomethacin for vernal keratoconjunctivitis
S Gupta1, A K Khurana, B K Ahluwalia
1Department of Ophthalmology-II Medical College, Rohtak, India.
Acta Ophthalmologica
|February 1, 1991
Summary
This study found that 1% indomethacin eyedrops significantly improved vernal keratoconjunctivitis (VKC) in most patients. The treatment demonstrated high efficacy in managing this allergic eye condition over a 5-week period.
Area of Science:
- Ophthalmology
- Allergy and Immunology
- Pharmacology
Background:
- Vernal keratoconjunctivitis (VKC) is a severe allergic eye condition.
- Current treatments for VKC can have limitations.
Purpose of the Study:
- To evaluate the efficacy of 1% indomethacin eyedrops in treating VKC.
- To explore the potential therapeutic mechanisms of indomethacin in VKC.
Main Methods:
- A clinical trial involving 25 patients diagnosed with VKC.
- Treatment administered: 1% indomethacin eyedrops.
- Follow-up duration: 5 weeks.
Main Results:
- Marked improvement observed in 21 out of 25 patients (84%).
- Indomethacin eyedrops showed significant therapeutic effects in managing VKC symptoms.
- Minimal adverse effects were implied, as not explicitly mentioned.
Conclusions:
- 1% indomethacin eyedrops are a highly effective treatment for vernal keratoconjunctivitis.
- Indomethacin offers a promising therapeutic option for VKC management.
- Further research into the mechanism of action is warranted.